Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,877 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients.
You R, Liu YP, Lin M, Huang PY, Tang LQ, Zhang YN, Pan Y, Liu WL, Guo WB, Zou X, Zhao KM, Kang T, Liu LZ, Lin AH, Hong MH, Mai HQ, Zeng MS, Chen MY. You R, et al. Among authors: lin ah, lin m. Int J Cancer. 2019 Nov 15;145(10):2873-2883. doi: 10.1002/ijc.32380. Epub 2019 Jun 10. Int J Cancer. 2019. PMID: 31044420
Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M, You R, Liu YP, Zhang YN, Zhang HJ, Zou X, Yang Q, Li CF, Hua YJ, Yu T, Cao JY, Li JB, Mo HY, Guo L, Lin AH, Sun Y, Qian CN, Ma J, Mai HQ, Chen MY. Lin M, et al. Among authors: lin ah. Oral Oncol. 2018 May;80:1-8. doi: 10.1016/j.oraloncology.2018.03.002. Epub 2018 Mar 13. Oral Oncol. 2018. PMID: 29706183
Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X, Hong MH, Chen MY. Yang Q, et al. Among authors: lin zx, lin m. Eur J Cancer. 2019 Sep;119:87-96. doi: 10.1016/j.ejca.2019.07.007. Epub 2019 Aug 16. Eur J Cancer. 2019. PMID: 31425966 Clinical Trial.
Clonal Mutations Activate the NF-κB Pathway to Promote Recurrence of Nasopharyngeal Carcinoma.
You R, Liu YP, Lin DC, Li Q, Yu T, Zou X, Lin M, Zhang XL, He GP, Yang Q, Zhang YN, Xie YL, Jiang R, Wu CY, Zhang C, Cui C, Wang JQ, Wang Y, Zhuang AH, Guo GF, Hua YJ, Sun R, Yun JP, Zuo ZX, Liu ZX, Zhu XF, Kang TB, Qian CN, Mai HQ, Sun Y, Zeng MS, Feng L, Zeng YX, Chen MY. You R, et al. Among authors: lin dc, lin m. Cancer Res. 2019 Dec 1;79(23):5930-5943. doi: 10.1158/0008-5472.CAN-18-3845. Epub 2019 Sep 4. Cancer Res. 2019. PMID: 31484669
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
You R, Liu YP, Huang PY, Zou X, Sun R, He YX, Wu YS, Shen GP, Zhang HD, Duan CY, Tan SH, Cao JY, Li JB, Xie YL, Zhang YN, Wang ZQ, Yang Q, Lin M, Jiang R, Zhang MX, Hua YJ, Tang LQ, Zhuang AH, Chen QY, Guo L, Mo HY, Chen Y, Mai HQ, Ling L, Liu Q, Chua MLK, Chen MY. You R, et al. Among authors: lin m. JAMA Oncol. 2020 Sep 1;6(9):1345-1352. doi: 10.1001/jamaoncol.2020.1808. JAMA Oncol. 2020. PMID: 32701129 Free PMC article. Clinical Trial.
Neoantigen landscape in metastatic nasopharyngeal carcinoma.
Lin M, Zhang XL, You R, Yang Q, Zou X, Yu K, Liu YP, Zou RH, Hua YJ, Huang PY, Wang J, Zhao Q, Jiang XB, Tang J, Gu YK, Yu T, He GP, Xie YL, Wang ZQ, Liu T, Chen SY, Zuo ZX, Chen MY. Lin M, et al. Theranostics. 2021 Apr 19;11(13):6427-6444. doi: 10.7150/thno.53229. eCollection 2021. Theranostics. 2021. PMID: 33995666 Free PMC article.
16,877 results
You have reached the last available page of results. Please see the User Guide for more information.